Last reviewed · How we verify
Aldara — Competitive Intelligence Brief
marketed
imiquimod
7,8-dihydro-8-oxoguanine triphosphatase
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Aldara (IMIQUIMOD) — Bausch Health. Aldara works by activating the immune system to recognize and attack abnormal cells.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Aldara TARGET | IMIQUIMOD | Bausch Health | marketed | imiquimod | 7,8-dihydro-8-oxoguanine triphosphatase | 1997-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Aldara · 8598196 · Method of Use · US
- — Aldara · 10238645 · Method of Use · US
- — Aldara · 8299109 · Method of Use · US
- — Aldara · 11318130 · Method of Use · US
- — Aldara · 8236816 · Method of Use · US
- — Aldara · 8222270 · Method of Use · US
- — Aldara · 10238644 · Method of Use · US
- — Aldara · 10918635 · Method of Use · US
- — Aldara · 11850245 · Method of Use · US
- — Aldara · 11202752 · Method of Use · US
Sponsor landscape (imiquimod class)
- Bausch Health · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Aldara CI watch — RSS
- Aldara CI watch — Atom
- Aldara CI watch — JSON
- Aldara alone — RSS
- Whole imiquimod class — RSS
Cite this brief
Drug Landscape (2026). Aldara — Competitive Intelligence Brief. https://druglandscape.com/ci/imiquimod. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab